Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Monopar Therapeutics (NASDAQ:MNPR) from a hold rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.

Several other brokerages have also issued reports on MNPR. HC Wainwright boosted their target price on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Cantor Fitzgerald lowered Monopar Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $109.00 to $119.00 in a research note on Thursday, August 13th. Zacks Research cut Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Barclays reaffirmed an “overweight” rating and issued a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a research report on Friday, September 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $122.00.

Monopar Therapeutics Trading Down 6.0%

Monopar Therapeutics stock opened at $78.96 on Friday. The firm has a 50-day moving average price of $104.34 and a 200-day moving average price of $83.50. The firm has a market capitalization of $529.82 million, a PE ratio of -36.39 and a beta of 1.50. Monopar Therapeutics has a 12-month low of $50.07 and a 12-month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. As a group, sell-side analysts predict that Monopar Therapeutics will post -2.98 earnings per share for the current fiscal year.

Insider Activity at Monopar Therapeutics

In other Monopar Therapeutics news, CEO Chandler Robinson sold 29,056 shares of the firm’s stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $88.00, for a total transaction of $2,556,928.00. Following the transaction, the chief executive officer directly owned 99,267 shares in the company, valued at $8,735,496. This trade represents a 22.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim R. Tsuchimoto sold 4,090 shares of Monopar Therapeutics stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total value of $455,585.10. Following the sale, the director directly owned 7,396 shares of the company’s stock, valued at approximately $823,840.44. This trade represents a 35.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 44,688 shares of company stock worth $4,023,094. Insiders own 9.70% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new position in shares of Monopar Therapeutics during the second quarter valued at $7,124,000. Siren L.L.C. lifted its stake in Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares during the period. Bank of America Corp DE lifted its stake in Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after acquiring an additional 53,336 shares during the period. ADAR1 Capital Management LLC grew its holdings in Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after acquiring an additional 30,370 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in Monopar Therapeutics during the 1st quarter valued at about $3,458,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.